CODEXIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.66 USD | +0.38% |
|
-6.01% | -12.79% |
| 04-11 | Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board | CI |
| 02-29 | Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9 | MT |
| Sales 2024 * | 65.38M 5.23B | Sales 2025 * | 62.05M 4.97B | Capitalization | 188M 15.02B |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -3.68B | Net income 2025 * | -49M -3.92B | EV / Sales 2024 * | 2.87 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.02 x |
| P/E ratio 2024 * |
-4.13
x | P/E ratio 2025 * |
-3.89
x | Employees | 174 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Codexis, Inc.
More recommendations
More press releases
More news
| 1 day | +0.38% | ||
| 1 week | -6.01% | ||
| Current month | -23.78% | ||
| 1 month | -24.22% | ||
| 3 months | -4.32% | ||
| 6 months | +71.61% | ||
| Current year | -12.79% |
1 week
2.62
3.03
1 month
2.573.54
Current year
2.534.91
1 year
1.454.91
3 years
1.4542.01
5 years
1.4542.01
10 years
1.3442.01
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Dilly
CEO | Chief Executive Officer | 64 | 15/06/20 |
Sriram Ryali
DFI | Director of Finance/CFO | 43 | 22/01/23 |
| Compliance Officer | 53 | 31/10/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Smith
BRD | Director/Board Member | 64 | 29/02/16 |
Rahul Singhvi
BRD | Director/Board Member | 59 | 27/09/22 |
Stephen Dilly
CEO | Chief Executive Officer | 64 | 15/06/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.09% | 1 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.66 | +0.38% | 513,816 |
| 25/04/24 | 2.65 | -5.36% | 281,863 |
| 24/04/24 | 2.8 | -3.45% | 213,703 |
| 23/04/24 | 2.9 | +1.40% | 192,442 |
| 22/04/24 | 2.86 | +1.06% | 204,345 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.66
USD
Average target price
6.571
USD
Spread / Average Target
+147.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.79% | 188M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CDXS Stock
